Article

Mark Zitter Addresses How Oncology Payers Are Becoming Stricter About Covered Therapies

Mark Zitter, Founder and CEO of The Zitter Group, in San Francisco and Millburn, NJ, discusses how oncology payers are tightening the reins with approval requirements and the delicacy involved in revising guidelines around cancer care.

Mr. Zitter talks about several of the payers' changes, which include prior authorizations, clinical guidelines, and decision-support programs. He also addresses the ongoing friction between payers and providers and how critical it is to find resolution.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Sundar Jagannath
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
Hadar Avihai Lev-Tov, MD
Ayodeji Adegunsoye, MD, PhD, MSc
David J. Maron, MD, FASPC, Stanford University School of Medicine
Hadar Avihai Lev-Tov, MD
Senator Vincent Polistina (R, New Jersey)
Related Content
The investigators said they believe their scoring system to be a useful tool that will improve patient care. | Image Credit: mi_viri
July 30th 2025

AIM-30 Score Predicts Mortality Following Acute Exacerbation of IPF

Jared Kaltwasser
Factors such as age, smoking status, and body mass index can help clinicians predict a patient’s risk of 30-day mortality.
managed care cast logo
July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM
This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.
Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com
July 29th 2025

Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

Jared Kaltwasser
Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the association is necessarily a causal one.
Managed Care Cast
Published: July 15th 2025 | Updated: July 15th 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey
Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization
As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
July 29th 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor
Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.
IPF and PPF both face poor survival rates, and the pair share similar clinical features, leading to similar treatment approaches, which are limited and nuanced. | Image credit: Sebra - stock.adobe.com
July 29th 2025

Setting Care Goals Early Is Key in Pulmonary Fibrosis

AJMC Contributor
With limited treatment options and potential for admission to the intensive care unit, researchers of a new paper highlighted the importance of discussing goals and initiating palliative care early on.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo